Equity
€286,424 ▲ 17.8%
SCIEMPATH BIO has made a profit in every financial year since 2015.
SCIEMPATH BIO
Overview
Lifetime
10 annual accounts with figures on one time axispeak €129,873 (2021)
€49,134▲ 10.7%
peak €198,055 (2021)
€93,217▼ 8.7%
peak €293,997 (2021)
€286,424▲ 17.8%
€322,177▲ 8.0%
Board1 name since 2021
1 directorRICHARD Virgile Bernard
Documentsfilings and deeds
28-08-202528 days late
2024micro format
Change of role: RICHARD Virgile Bernard, from manager to dire… 12-02Dividend €50,000Equity from €243,206 to €286,424Investments €18,483Cash from €252,906 to €440,084
Key points
from the 2024 annual accountsInvestments
€24,700 8.9 × depreciation
Green is investment, beige is depreciation.
Filings
10 annual accounts 103 days past the deadline
2025 accounts not filed: deadline was 31-07-2026.
Checked score
56
Fair
Financially stronger than 60% of micro companies in research and development (NACE 72)
Probability in this band: 1.5% to 4.2%
A confirmed filing finding caps the score at 59.
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 932 companies (NACE 72, micro).
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.2%▲ +0.1 percentage points vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025
08-2025: 0.2%● unchanged vs 07-2025
09-2025: 0.3%▲ +0.1 percentage points vs 08-2025highest value
10-2025: < 0.1%▼ -0.3 percentage points vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026lowest value
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: 0.1%▲ +0.1 percentage points vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.2%▲ +0.1 percentage points vs 09-2026
11-2026: 0.2%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Capped at 59: a confirmed filing finding
Figures for financial year 2024 (filed on 04-09-2025)
lowers risk
Liquidity: current ratio 1.70, cash €440,084
Sector: Scientific research and development (NACE 72)
Size: total assets €608,601
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 43% of them on solvency, 61% on liquidity, 67% on profitability and 70% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2024.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 17,811 companies had the same profile as SCIEMPATH BIO has now. Each dot stands for 45 companies, two years later.
96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
That fits the bankruptcy probability of SCIEMPATH BIO itself: 0.2% within 12 months.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,811 companies, not a prediction for SCIEMPATH BIO. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €16,000 on 30-day terms, only on tighter conditions: an expected filing is missing beyond Checked's processing allowance
Liquidity is ample, with a current ratio of 1.7 (1.67 in 2023), above the usual 1.5. Short-term debt is 52.9% and cash 72.3% of total assets. However, 52.9% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
raises risk · Annual accounts not filed
The financial year that closed on 31-12-2025 was due at the National Bank by 31-07-2026. Nothing is on record, 103 days later.
NBB · 10 filingsPosition against the passed deadline
31-12-2025 year end31-07-2026 deadline11-11-2026 today
raises risk · 2024 accounts filed 28 days late
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 28-08-2025, 28 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
not filed
2024
28 days late
2023
26 days late
2022
63 days late
2021
31 days late
2020
44 days late
2019
12 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 6 accounts on average 34 days after the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (1)
Recent changes
Change of role: RICHARD Virgile Bernard, from manager to director
“Les services et consultations en pathologie investigative,expérimentale,moléculaire et toxicologique ainsi que…” (deed in French) · General meeting of 26-01-2024 · Gazette deed
First establishment
Incorporation
published on 19-09-2014 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| SCIEMPATH BIO Braine-l'Alleud | €608,601 | €49,134 | 47.1% | - |
| SINTAC Nivelles | €575,707 | €91,555 | 96.8% | - |
| ECSOR Chastre | €456,113 | €40,107 | 26.3% | - |
| Sevann Knokke-Heist | €663,053 | €67,063 | 94.4% | - |
| Dr. Stefanie Vanderbauwhede Kortrijk | €355,078 | €43,496 | 88.8% | - |
| 4U2 PATENT SERVICE Oudenaarde | €472,883 | €110,277 | 87.0% | - |
| JMJ CONCEPT Chastre | €664,788 | €135,085 | 83.1% | - |
These companies have the same main activity as SCIEMPATH BIO: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €355,000 and €665,000, founded between 2010 and 2015.
Official details
Source: KBO- Status
- Active since 18-08-2014Normal situation
- Activity
- Other research and development on natural sciencesNACE 72109
- Establishment unit
- 2.235.707.369since 09-09-2014
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Annual accounts 2024
- €49,134▲ 10.7%
- ≈ €200,000estimated
- €93,217▼ 8.7%
- €286,424▲ 17.8%
- €608,601▲ 12.4%
- Filing
- Filed on 28-08-2025
Insights on SCIEMPATH BIO
SCIEMPATH BIO files the micro format. That format states no turnover. The gross margin fell from €55,504 in 2015 to €49,134 in 2024.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2024
micro format, filed on 28-08-2025, 28 days late2025 annual accounts not yet filed, deadline passed on 31 July 2026 The financial year closed on 31 December 2025. The accounts are due at the latest 7 months after the close (Companies Code art. 3:10). Source: NBB filings, as of 11 November 2026.
€49,134
▲ 10.7%
€38,724
▲ 3.2%
€93,217
▼ 8.7%
€224,386
▲ 13.1%
47.1%
▲ 2.1 percentage points
1.70
▲ 0.03
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €200,000. Estimated: probably between €120,000 and €360,000.
Balance sheet
balance sheet total €608,601 on 31-12-2024What the company ownsHow it is paid for
in euro
in euro
Position in the sector
47.1%
Higher than 37% of 626 companies in 2024.
1.70
Higher than 34% of 607 companies in 2024.
15.3%
Higher than 60% of 613 companies in 2024.
SCIEMPATH BIO
Middle half of the sector
80% of the sector
Micro accounts in research and development (NACE 72)
Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: middle half
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | |||||||||||
20/58 |
608,601 | 541,478 | 462,521 | 377,640 | 161,431 | 133,851 | 136,275 | 150,359 | 110,269 | 87,230 | |
21/28 |
62,038 | 46,330 | 51,649 | 44,341 | 43,887 | 45,396 | 65,163 | 81,492 | 67,800 | 36,970 | |
21 |
- | - | - | - | - | - | 1,600 | 4,000 | 7,311 | 11,076 | |
22/27 |
23,541 | 7,833 | 13,152 | 5,844 | 5,390 | 6,899 | 25,066 | 47,270 | 30,267 | 25,893 | |
23 |
- | - | - | - | - | - | - | - | 2,326 | 5,813 | |
24 |
23,539 | 6,799 | 10,770 | 1,958 | - | 4 | 16,668 | 37,368 | 16,535 | 16,472 | |
26 |
2 | 1,035 | 2,382 | 3,886 | 5,390 | 6,894 | 8,398 | 9,902 | 11,406 | 3,608 | |
28 |
38,497 | 38,497 | 38,497 | 38,497 | 38,497 | 38,497 | 38,497 | 30,222 | 30,222 | - | |
29/58 |
546,563 | 495,148 | 410,872 | 333,300 | 117,544 | 88,455 | 71,112 | 68,867 | 42,468 | 50,260 | |
40/41 |
106,479 | 242,242 | 150,151 | 220,159 | 926 | 68,525 | 25,045 | 5,061 | 11,520 | 1,844 | |
40 |
104,964 | 241,785 | 148,487 | 218,498 | - | 66,481 | 23,959 | 3,076 | 8,691 | - | |
41 |
1,516 | 457 | 1,664 | 1,662 | 926 | 2,044 | 1,086 | 1,985 | 2,829 | 1,844 | |
54/58 |
440,084 | 252,906 | 259,412 | 110,839 | 114,375 | 17,726 | 43,783 | 61,550 | 28,033 | 47,255 | |
490/1 |
- | - | 1,309 | 2,301 | 2,244 | 2,204 | 2,285 | 2,256 | 2,916 | 1,161 | |
| Balance sheet: equity and liabilities | |||||||||||
10/49 |
608,601 | 541,478 | 462,521 | 377,640 | 161,431 | 133,851 | 136,275 | 150,359 | 110,269 | 87,230 | |
10/15 |
286,424 | 243,206 | 241,090 | 293,997 | 145,942 | 106,770 | 112,469 | 110,382 | 88,677 | 55,091 | |
10/11 |
30,000 | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 | |
100 |
- | - | - | - | - | 30,000 | 30,000 | 30,000 | 30,000 | 30,000 | |
13 |
24,500 | 24,500 | 24,500 | 24,500 | 24,500 | 24,500 | 24,500 | 24,500 | 23,750 | 12,550 | |
130/1 |
3,000 | 3,000 | 3,000 | 3,000 | 3,000 | - | - | - | - | - | |
130 |
- | - | - | - | - | 3,000 | 3,000 | 3,000 | 2,250 | 1,050 | |
1311 |
3,000 | 3,000 | 3,000 | 3,000 | 3,000 | - | - | - | - | - | |
132 |
21,500 | 21,500 | 21,500 | 21,500 | 21,500 | 21,500 | 21,500 | 21,500 | 21,500 | 11,500 | |
14 |
231,924 | 188,706 | 186,590 | 239,497 | 91,442 | 52,270 | 57,969 | 55,882 | 34,927 | 12,541 | |
17/49 |
322,177 | 298,272 | 221,431 | 83,644 | 15,489 | 27,081 | 23,806 | 39,977 | 21,591 | 32,139 | |
17 |
- | - | - | - | - | - | 7,199 | 14,197 | - | - | |
170/4 |
- | - | - | - | - | - | 7,199 | 14,197 | - | - | |
42/48 |
322,177 | 296,787 | 221,431 | 83,517 | 15,489 | 26,983 | 16,511 | 24,447 | 21,591 | 32,043 | |
42 |
- | - | - | - | - | 7,199 | 6,998 | 6,803 | - | - | |
44 |
133 | 1,783 | - | 588 | 66 | 95 | 458 | 886 | 7,627 | 403 | |
440/4 |
133 | 1,783 | - | 588 | 66 | 95 | 458 | 886 | 7,627 | 403 | |
46 |
- | - | - | - | - | - | - | - | - | 2,481 | |
45 |
38,294 | 46,254 | 46,431 | 32,829 | 15,423 | 4,689 | 3,050 | 11,714 | 11,950 | 6,111 | |
450/3 |
21,191 | 25,091 | 46,431 | 32,829 | 15,423 | 4,689 | 3,050 | 11,714 | 11,950 | 6,111 | |
454/9 |
17,103 | 21,163 | - | - | - | - | - | - | - | - | |
47/48 |
283,750 | 248,750 | 175,000 | 50,100 | - | 15,000 | 6,006 | 5,044 | 2,015 | 23,048 | |
492/3 |
- | 1,485 | - | 127 | - | 98 | 96 | 1,334 | - | 96 | |
| Income statement | |||||||||||
76A |
- | - | - | - | - | - | 98 | - | - | - | |
9900 |
49,134 | 44,397 | 61,343 | 129,873 | 54,169 | 35,117 | 30,816 | 61,706 | 63,738 | 55,504 | |
630 |
2,775 | 5,319 | 2,543 | 1,612 | 1,508 | 19,767 | 24,604 | 29,286 | 17,300 | 17,863 | |
640/8 |
7,635 | 1,554 | 1,066 | 1,039 | 838 | 1,012 | 917 | 1,812 | 129 | 85 | |
9901 |
38,724 | 37,524 | 57,734 | 127,223 | 51,823 | 14,338 | 5,295 | 30,608 | 46,309 | 37,555 | |
75/76B |
62,938 | 74,009 | 78,198 | 101,239 | 0 | 1 | 1 | 0 | - | 475 | |
75 |
62,938 | 74,009 | 78,198 | 101,239 | 0 | 1 | 1 | 0 | - | 475 | |
65/66B |
1,157 | 533 | 574 | 776 | 1,010 | 1,460 | 1,659 | 557 | 3,684 | 1,179 | |
65 |
1,157 | 533 | 574 | 776 | 1,010 | 1,460 | 1,659 | 557 | 3,684 | 1,179 | |
9903 |
100,506 | 111,001 | 135,358 | 227,686 | 50,812 | 12,879 | 3,636 | 30,051 | 42,626 | 36,852 | |
67/77 |
7,288 | 8,885 | 13,264 | 29,631 | 11,640 | 3,578 | 1,549 | 8,346 | 9,039 | 4,761 | |
9904 |
93,217 | 102,116 | 122,093 | 198,055 | 39,172 | 9,301 | 2,087 | 21,705 | 33,586 | 32,091 | |
689 |
- | - | - | - | - | - | - | - | 10,000 | 11,500 | |
9905 |
93,217 | 102,116 | 122,093 | 198,055 | 39,172 | 9,301 | 2,087 | 21,705 | 23,586 | 20,591 | |
| Appropriation of the result | |||||||||||
9906 |
281,924 | 288,706 | 361,590 | 289,497 | 91,442 | 67,270 | 57,969 | 56,632 | 36,127 | 20,591 | |
14P |
188,706 | 186,590 | 239,497 | 91,442 | - | - | - | - | - | - | |
691/2 |
- | - | - | - | - | - | - | 750 | 1,200 | 1,050 | |
6920 |
- | - | - | - | - | - | - | 750 | 1,200 | 1,050 | |
694/7 |
50,000 | 100,000 | 175,000 | 50,000 | - | 15,000 | - | - | - | 7,000 | |
694 |
50,000 | 100,000 | 175,000 | 50,000 | - | 15,000 | - | - | - | - | |
695 |
- | - | - | - | - | - | - | - | - | 7,000 | |
| Document | |||||||||||
The notes to these accounts have 10 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).
Source: Annual accounts 2024 (PDF), filed on 28-08-2025.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2024 | micro format | 28-08-2025 | 2025-00479201 | |
| 31-12-2023 | micro format | 26-08-2024 | 2024-00429495 | |
| 31-12-2022 | micro format | 02-10-2023 | 2023-00472209 | |
| 31-12-2021 | micro format | 31-08-2022 | 2022-20422494 | |
| 31-12-2020 | micro format | 13-09-2021 | 2021-67500502 | |
| 31-12-2019 | micro format | 12-08-2020 | 2020-41800032 | |
| 31-12-2018 | micro format | 30-08-2019 | 2019-63300191 | |
| 31-12-2017 | micro format | 24-09-2018 | 2018-65600396 | |
| 31-12-2016 | micro format | 21-09-2017 | 2017-62300337 | |
| 31-12-2015 | full format | 10-06-2016 | 2016-17900227 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 41,499 | 42,843 | 60,277 | 128,834 | 53,331 | 34,105 | 29,899 | 59,894 | 63,609 | 55,419 | ||
| 95,992 | 107,435 | 124,637 | 199,666 | 40,681 | 29,068 | 26,691 | 50,991 | 50,886 | 49,954 | ||
| 24,700 | 0 | 9,852 | 2,065 | 0 | 0 | 8,275 | 42,978 | 48,130 | 54,833 | ||
| 187,178 | -6,505 | 148,572 | -3,536 | 96,648 | -26,056 | -17,768 | 33,517 | -19,223 | - | ||
| 224,386 | 198,361 | 189,441 | 249,783 | 102,055 | 61,472 | 54,601 | 44,420 | 20,877 | 18,217 | ||
| 47.1% | 44.9% | 52.1% | 77.9% | 90.4% | 79.8% | 82.5% | 73.4% | 80.4% | 63.2% | ||
| 1.70 | 1.67 | 1.86 | 3.99 | 7.59 | 3.28 | 4.31 | 2.82 | 1.97 | 1.57 | ||
| 1.12 | 1.23 | 0.92 | 0.28 | 0.11 | 0.25 | 0.21 | 0.36 | 0.24 | 0.58 | ||
| 32.5% | 42.0% | 50.6% | 67.4% | 26.8% | 8.7% | 1.9% | 19.7% | 37.9% | 58.3% | ||
| 15.3% | 18.9% | 26.4% | 52.4% | 24.3% | 6.9% | 1.5% | 14.4% | 30.5% | 36.8% | ||
| 35.87 | 80.44 | over 100 | over 100 | - | - | - | - | - | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tangible fixed assets | €24,700 | - | €9,852 | €2,065 |
| €2,775 | €5,319 | €2,543 | €1,612 |
Source: notes to the 2021 to 2024 annual accounts (statement of fixed assets)
Insights on SCIEMPATH BIO
The operating result for 2024 is 3% higher than in 2023. It is a recovery after the fall in 2023.
Debt's share of the balance-sheet total falls from 55.1% to 52.9%. Equity and debt are higher.
Board & ownership
Board
1 director, last change in 2024Director (not named in the articles)
appointed by deed of 12-02-2024
earlier manager, until 12-02-2024
listed in the 2024 annual accounts, filed on 28-08-2025
Mandates through the years
1 name, the dashed line is todayRICHARD Virgile Bernard
Director (not named in the articles)
Director (not named in the articles)
BoardEarliermandate already running before its first mention
Mandates as a list
- RICHARD Virgile Bernard
- Director (not named in the articles), since before 31-12-2021
- Manager, until 12-02-2024
Control
Capital
- Contribution
- €30,000
- Source
- 2024 annual accounts
Articles of association
deed of 12-02-2024 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Moitié cédant,moitié acquéreurs proportionnellement si plusieurs, tenus de solliciter agrément mêmes formalités si non actionnaires de plein…”
Network & group
No group
SCIEMPATH BIO has no parent and no holdings in its annual accounts. RICHARD Virgile Bernard is the only director. SCIEMPATH BIO shares no director with another company.
Timeline
Timeline
18 events since 2014Board
Filings
Financial
Establishments
2014201620182020202220242026
2025
Annual accounts 2024 filed PDFmicro format · 28 days late
2024
Annual accounts 2023 filed PDFmicro format · 26 days late
Change of role: RICHARD Virgile Bernard, from manager to director“Les services et consultations en pathologie investigative,expérimentale,moléculaire et toxicologique ainsi que…” (deed in French) · General meeting of 26-01-20246 points ▸
- General meeting, 26-01-2024
- 100 shares
- Capital, €33,000
- Director appointment, RICHARD Virgile Bernard (director (not named in the articles))
- Director resignation, RICHARD Virgile Bernard (manager)
- Registered office clause, Grand’Route 99, 1428 Braine-l'Alleud
- The deed holds 4 more points.
2023
Annual accounts 2022 filed PDFmicro format · 63 days late
2022
Annual accounts 2021 filed PDFmicro format · 31 days late
2021
Highest result from 2015 to 2024 net €198,055 ▲406% The operating result of €127,223 and the net result of €198,055 are both a record.
Equity above €200,000 equity €293,997 ▲101% Equity rises from €145,942 to €293,997.
Annual accounts 2020 filed PDFmicro format · 44 days late
2020
Liquidity more than doubled current ratio 7.59 The current ratio rises from 3.28 to 7.59. Short-term debt falls from €26,983 to €15,489.
Annual accounts 2019 filed PDFmicro format · 12 days late
2019
Annual accounts 2018 filed PDFmicro format · 30 days late
2018
Weakest financial year net €2,087 ▼90.4% The net result drops to €2,087, the lowest from 2015 to 2024. It recovers the following year.
Annual accounts 2017 filed PDFmicro format · 55 days late
2017
Equity above €100,000 equity €110,382 ▲24.5% With a profit in every financial year since 2015, equity grows to €110,382.
Annual accounts 2016 filed PDFmicro format · 52 days late
2016
Annual accounts 2015 filed PDFfull format · 51 days before the deadline
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Identity
- Enterprise number
- 0561.779.953
- VAT number
- BE 0561.779.953
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 18-08-2014
- Financial year
- ends on 31 December
- Peppol
- Not found in the Peppol Directory
- Name
- SCIEMPATH BIO in French
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 12-02-2024 (in French)
Activities
NACEBEL 202572109
Other research and development on natural sciences main activity
Codes under NACEBEL 2008
72190
Scientific research and development main activity
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “Les services et consultations en pathologie investigative,expérimentale,moléculaire et toxicologique ainsi que dans le domaine des…”deed of 12-02-2024 (in French)
3 activities
- Les services et consultations en pathologie investigative,expérimentale,moléculaire et toxicologique ainsi que dans le domaine des biomarqueurs pour les entreprises privées et publiques œuvrant dans les domaines bio-médical et pharmaceutiques
- L’activité de traiteur,la préparation de plats à emporter,la livraison de repas aux particuliers et professionnels,la commercialisation de tous produits et spécialités culinaires
- L’organisation et l’animation d’ateliers de cuisine
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Grand'Route 99 registered office 1428 Braine-l'Alleud | ||
| SCIEMPATH BIO | 09-09-2014 | 2.235.707.369 |
Buildings and parcels at the addresses
- Ground area
- 8,122 m²
- Buildings
- 925 m²
- Volume, LiDAR
- 12,893 m³
- Tallest building
- 18.0 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 25744D0293/00R003 | 7,876 m² | 1 · 860 m² | 17.9 m · 5 |
| 25054D0159/00S002 | 246 m² | 1 · 65 m² | 11.2 m · 3 |